May 22, 2014
A Pennsylvania federal judge on Wednesday agreed to dismiss a putative class action claiming that Cephalon Inc. caused a workers' benefit fund to pay increased prescription costs for the powerful opioid Fentora by fraudulently marketing the drug for off-label uses, ruling that the plaintiff didn't adequately allege a scheme to defraud.